Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Trial Profile

Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Defactinib (Primary) ; Gemcitabine; Pembrolizumab
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Aug 2018 According to Verastem media release, the expansion phase of the study is now ongoing.
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2018 According to Verastem media release, data from this trial will be preasented at ASCO 2018 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top